NCT03526250: Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

NCT03526250
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+, ATM, ALK, EZH2, FGFR, MAPK, mTOR, NTRK, PI3K, RAF, ROS, TSC, DNA damage repair mutations, Rb+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Months to 21 Years (Child, Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients over the age of 21
https://ClinicalTrials.gov/show/NCT03526250

Comments are closed.

Up ↑